Effect of Anti-tuberculosis Drugs on Liver Damage Based on Alanine Aminotransferase Level in Pulmonary Tuberculosis Patients

Vera Dianwari; Vycke Yunivita Kusumah Dewi; Nia Kania

doi:10.15850/amj.v4n4.1259

Effect of Anti-tuberculosis Drugs on Liver Damage Based on Alanine Aminotransferase Level in Pulmonary Tuberculosis Patients

Vera Dianwari, Vycke Yunivita Kusumah Dewi, Nia Kania

Abstract

Background: Antituberculosis (anti-TB) drugs could cause serious effect such as hepatotoxicity signed by the increase of Alanine Aminotransferase (ALT) level. Anti-TB drugs are still needed by TB patients who have hepatotoxicity, although clinicians who manage this condition have not recognize whether the advantage of anti-TB drugs is higher than its adverse effect, and there is no data describing about that issue. This study was conducted to discover the liver damage based on the ALT changes before and 12 days after initial anti-TB treatment.

Methods: This was a cross-sectional study with total sampling of medical records of pulmonary tuberculosis inpatients from 1st January 2013–31th December 2014 at the Department of Internal Medicine of Dr. Hasan Sadikin.General Hospital. From 141 data, only 14 medical records were eligible to be included in this study. The data used were ALT level before and after therapy. These data were analyzed using Wilcoxon test and considered as significant if p<0.05.

Results: The median age of the subject study was 48(18-65) years. Among 14 patients, 8 were female and 6 were male. Five out of fourteen patients developed hepatotoxicity. Four out of five developed grade 1 hepatotoxicity and one out of five developed hepatotoxicity grade 4. The analysis of the data showed the differences of ALT level before anti-TB therapy (22(4-447)) and 12 days after initial therapy (18.5(4-1206)) was not significant (p=0.660).

Conclusions: There is no liver damage based on ALT changes after anti-TB treatment so the treatment can be continued.

Keywords

Alanine aminotransferase, antituberculosis drugs; hepatotoxicity; tuberculosis

Full Text:

PDF

References

ementrian Kesehatan Republik Indonesia. Pedoman Nasional Penanggulangan Tuberkulosis. Jakarta: Bakti Husada, 2014.

World Health Organization. Global Tuberculosis Report 2014. France: WHO, 2015.

Sari ID, Yuniar Y, Syaripuddin M. Studi monitoring efek samping obat antituberkulosis fdc kategori 1 di Provinsi Banten dan Provinsi Jawa Barat. Media Litbang. 2014;24(1):28–35.

Khoharo HK, Ansari S, Siddiqui AA, Qureshi F. Standard antituberculosis drug induced hepatotoxicity : do the risk factors matter. J Liaquat Univ Med Heal Sci. 2010;09(2):84–7.

Singh A, Bhat TK, Sharma OP. Clinical biochemistry of hepatotoxicity. J Clin Toxicol. 2011;1(3):1-19

Mahmood K, Hussain A, Jairamani KL. Hepatotoxicity with antituberculosis drugs: the risk factors. Pak J Med Sci. 2007;23(1):33–8.

Núñez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44(1 Suppl):S132–9.

Wang C-S, Chen H-C, Yang C-J, Tsai J-R, Chong I-W, Hwang J-J, et al. Clinical characteristics of pulmonary tuberculosis patients from a southern Taiwan hospital-based survey. Kaohsiung J Med Sci. 2008;24(1):17–24.

Abbasi A, Moradi A, Kabir, MJ. Characteristic of Pulmonary Tuberculosis Patients in Golestan Province of Iran, 2002-2005. J Med Sci. 2006;6(4):698-700.

Gülbay BE, Gürkan ÖU, Yildiz ÖA, Önen ZP, Erkekol FO, Baççioǧlu A, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006;100(10):1834–42.

Nahar BL, Hossain AM, Islam MM, Saha DR. A comparative study on the adverse effects of two anti-tuberculosis drugs regimen in initial two-month treatment period. Bangladesh J Pharmacol. 2008;1(2):51–7.

Gulati K, Ray A, Vijayan VK. Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction. Indian J Exp Biol. 2010;48(3):318–22.

Enriquez-Cortina C, Almonte-Becerril M, Clavijo-Cornejo D, Palestino-Dominguez M, Bello-Monroy O, Nuno N, et al. Hepatocyte growth factor protects against isoniazid/rifampicin-induced oxidative liver damage. Toxicol Sci. 2013;135(1):26–36.

Kumar AKH, Sudha V, Ramachandram G. Simple and rapid method for simultaneous determination of isoniazid and acetyl isoniazid in urine by HPLC. Asian J Biomed Pharm Sci. 2014;4(34):46–50.

DOI: https://doi.org/10.15850/amj.v4n4.1259